Together, these results suggest that combining conventional chemotherapy with an AREG‐ or PD‐L1/PD‐1‐targeting agent has the competency to enhance tumor response without causing severe in vivo cytotoxicity. The gene discussed is PDCD1; the disease is neoplasm.